3D-QSAR and Docking Studies on the HEPT Derivatives of HIV-1 Reverse Transcriptase

Chemical Biology and Drug Design

Volumn 78, Issue 3, 2011, Pages 418-426

  Sree Latha, Ramaswamy ^a   Vijayaraj, Ramadoss ^b   Azhagiya Singam, Ettayapuram Ramaprasad ^b   Chitra, Krishnaswamy ^c   Subramanian, Venkatesan ^b  

^a BHARATH UNIVERSITY   (India)

^b CENTRAL LEATHER RESEARCH INSTITUTE   (India)

^c LN Government College   (India)

Author keywords

Comparative molecular field analysis; Docking; HEPT; HIV 1 RT; Quantitative structure activity relationship

Indexed keywords

1 (2 HYDROXYETHYLOXYMETHYL) 6 PHENYLTHIOTHYMINE DERIVATIVE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ARTICLE; COMPARATIVE MOLECULAR FIELD ANALYSIS; DRUG BINDING; DRUG DESIGN; ENZYME CONFORMATION; ENZYME STRUCTURE; MOLECULAR DOCKING; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; STATIC ELECTRICITY; THREE DIMENSIONAL IMAGING;

ANTI-HIV AGENTS; DRUG DESIGN; HIV INFECTIONS; HIV REVERSE TRANSCRIPTASE; HIV-1; HUMANS; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 80051581507     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01162.x     Document Type: Article

References (54)

1. Fauci S. (1998) The human immunodeficiency virus: infectivity and mechanisms of pathogenesis. Science;239:617-622.
2. De Clercq E. (1995) Toward improved anti-HIV chemotherapy: therapeutic strategies for intervention with HIV infections. J Med Chem;38:2491-2517.
3. Moore J.P., Stevenson M. (2000) New targets for inhibitors of HIV-1 replication. Nat Rev Mol Cell Biol;1:40-49.
4. Castro H.C., Loureiro N.I., Pujol-Luz M., Souza A.M., Albuquerque M.G., Santos D.O., Cabral L.M., Frugulhetti I.C., Rodrigues C.R. (2006) HIV-1 reverse transcriptase: a therapeutical target in the spotlight. Curr Med Chem;13:313-324.
5. Mitsuya H., Yarchoan R., Hayashi S., Broder S. (1990) Antiviral therapy against HIV infection. J Am Acad Dermatol;22:1282-1294.
6. Mitsuya H., Weinhold K.J., Furman P.A., St Clair M.H., Nusinoff-Lehrman S., Gallo R.C., Bolognesi D., Barry D.W., Broder S. (1985) 3'-Azido-3'-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc Natl Acad Sci USA;82:7096-7100.
7. Mitsuya H., Broder S. (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2', 3'-dideoxynucleosides. Proc Natl Acad Sci USA;83:1911-1915.
8. Yarchoan R., Mitsuya H., Thomas R.V., Pluda J.M., Hartman N.R., Perno C.F., Marczyk K.S., Allain J.P., Johns D.G., Broder S. (1989) In vivo activity against HIV and favorable toxicity profile of 2', 3'-dideoxyinosine. Science;245:412-415.
9. Coates J.A.V., Cammack N., Jenkinson H.J., Mutton I.M., Pearson B.A., Storer R., Cameron J.M., Penn C.R. (1992) The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother;36:202-205.
10. Baba M., Tanakas H., De Clercq E., Pauwels R., Balzarini J., Schols D., Nakashima H., Perno C.F., Walker R.T., Miyasaka T. (1989) Highly specific inhibition of human immunodeficiency virus type-1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun;165:1375-1381.
11. Pauwels R., Andries K., Desmyter J., Schols D., Kukla M.J., Breslin H.J., Raeymaeckers A., Van Gelder J., Woestenborghs R., Heykants J. (1990) Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature;343:470-474.
12. Merluzzi V.J., Hargrave K.D., Labadia M., Grozinger K., Skoog M., Wu J.C., Shih C.K., Eckner K., Hattox S., Adams J. (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science;250:1411-1413.
13. Romero D.L., Busso M., Tan C.K., Reusser F., Palmer J.R., Poppe S.M., Aristoff P.F., Downey K.M., So A.G., Resnick L., Tarpley W.G. (1991) Nonnucleoside reverse transcriptase inhibitors that potently and specifically block human immunodeficiency virus type 1 replication. Proc Nat Acad Sci;88:8806-8810.
14. Balzarini J., Pe' rez-Pe' rez M.J., San-Felix A., Schols D., Perno D.C.F., Vandamme A., Camarasa M.J., De Clercq E. (1992) 2', 5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″, 2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc Natl Acad Sci USA;89:4392-4396.
15. Pauwels R., Andries K., Debyser Z., Van Daele P., Schols D., Vandamme A.M., Janssen C.G.M., Anne J., Cauwenbergh G., Desmyter J., Heykants J., Janssen M.A.C., De Clercq E., Janssen P.A.J. (1993) Potent and highly selective human immunodeficiency virus type 1 (HIV-1) inhibition by a series of alpha-anilinophenylacetamide derivatives targeted at HIV-1 reverse transcriptase. Proc Natl Acad Sci USA;90:1711-1715.
16. Kleim J.P., Bender R., Billhardt U.M., Meichsner C., Riess G., Rosner M., Winkler I., Paessens A. (1993) Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob Agents Chemother;37:1659-1664.
17. Ahgren C., Backro K., Bell F.W., Cantrell A.S., Clemens M., Colacino J.M., Deeter J.B., Engelhardt J.A., Hogberg M., Jaskunas S.R., Johanssons N.G. (1995) The PETT series, a new class of potent nonnucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother;39:1329-1335.
18. Young S.D., Britcher S.F., Tran L.O., Payne L.S., Lumma W.C., Lyle T.A., Huff J.R., Anderson P.S., Olsen D.B., Carroll S.S. (1995) L-743, 726 (DMP-266): a novel, highly potent nonnucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother;39:2602-2605.
19. Frank K.B., Noll G.J., Connell E.V., Sim I.S. (1991) Kinetic interaction of human immunodeficiency virus type 1 reverse transcriptase with the antiviral tetrahydroimidazo[4, 5, 1-jk]-[1, 4]-benzodiazepine-2-(1H)-thione compound, R82150. J Biol Chem;266:14232-14236.
20. Althaus I.W., Chou J.J., Gonzales A.J., Deibel M.R., Chou K.C., Kezdy F.J., Romero D.L., Aristoff P.A., Tarpley W.G., Reusser F. (1993) Steady-state kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-87201E. J Biol Chem;268:6119-6124.
21. Spence R.A., Kati W.M., Anderson K.S., Johnson K.A. (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science;267:988-993.
22. Kohlstaedt L.A., Wang J., Friedman J.M., Rice P.A., Steitz T.A. (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science;256:1783-1790.
23. Smerdon S.J., Jager J., Wang J., Kohlstaedt L.A., Chirino A.J., Friedman J.M., Rice P.A., Steitz T.A. (1994) Structure of the binding site for nonnucleoside inhibitors of the reverse transcriptase of human immunodeficiency virus type 1. Proc Natl Acad Sci USA;91:3911-3915.
24. Ren J.S., Esnouf R., Garman E., Jones Y., Somers D., Ross C., Kirby I., Keeling J., Darby G., Stuart D., Stammers D. (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol;2:293-302.
25. Ding J., Das K., Tantillo C., Zhang W., Clark A.D.J., Jessen S., Lu X. et al. (1995) Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor α-APA R 95845 at 2.8 å resolution. Structure;3:365-379.
26. Ding J., Das K., Moereels H., Koymans L., Andries K., Janssen P.A.J., Hughes S.H., Arnold E. (1995) Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol;2:407-415.
27. Ren J.S., Esnouf R., Hopkins A., Ross C., Jones Y., Stammers D., Stuart D. (1995) The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design. Structure;3:915-926.
28. Smith M.S., Brian E.L., Pagano J.S. (1987) Resumption of virus production after human immunodeficiency virus infection of T lymphocytes in the presence of azidothymidine. J Virol;61:3769-3773.
29. Vasudevachari M.B., Battista C., Lane H.C., Psallidopoulos M.C., Zhao B., Cook J., Palmer J.R., Romero D.L., Tarpley W.G., Salzman N.P. (1992) Prevention of the spread of HIV-1 infection with nonnucleoside reverse transcriptase inhibitors. Virology;190:269-277.
30. Balzarini J., Karlsson A., Pe'rez-Pe'rez M.J., Camarasa M.J., De Clercq E. (1993) Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology;196:576-585.
31. Bacherler L., Jeffrey S., Hanna G., D'Aquila R., Wallace L., Logue K., Cordova B., Hertogs K., Larder B., Buckery R., Baker D., Gallagher K., Scarnati H., Tritch R., Rizzo C. (2001) Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol;75:4999-5008.
32. Rodriguez-Barrios F., Balzarini J., Gago F. (2005) The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations. J Am Chem Soc;127:7570-7578.
33. Miyasaka T., Tanaka H., Baba M., Hayakawa H., Walker R.T., Balzarini J., De Clercq E. (1989) A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine. J Med Chem;32:2507-2509.
34. Hannongbuaa S., Pungpoa P., Limtrakula J., Wolschann P. (1999) Quantitative structure-activity relationships and comparative molecular field analysis of TIBO derivatised HIV-1 reverse transcriptase inhibitors. J Comput Aided Mol Des;13:563-577.
35. Garg R., Gupta S.P., Gao H., Babu M.K., Debnath A.K., Hansch C. (1999) Comparative quantitative structure-activity relationship studies on anti-HIV drugs. Chem Rev;99:3525-3601.
36. Roy K., Leonard J.T. (2004) QSAR modeling of HIV-1 reverse transcriptase inhibitor 2-amino-6-arylsulfonylbenzonitriles and congeners using molecular connectivity and E-sate parameters. Bioorg Med Chem;12:745-754.
37. Gayen S., Debnath B., Samanta S., Jha T. (2004) QSAR study on some anti-HIV HEPT analogues using physicochemical and topological parameters. Bioorg Med Chem;12:1493-1503.
38. Juan A.A.S. (2008) 3D-QSAR models on clinically relevant K103N mutant HIV-1 reverse transcriptase obtained from two strategic considerations. Bioorg Med Chem Lett;18:1181-1194.
39. Hua R., Doucet J.P., Delamar M., Zhang R. (2009) QSAR models for 2-amino-6-arylsulfonylbenzonitriles and congeners HIV-1 reverse transcriptase inhibitors based on linear and nonlinear regression methods. Eur J Med Chem;44:2158-2171.
40. Sabet R., Fassihi A., Moeinifard B. (2009) QSAR study of PETT derivatives as potent HIV-1 reverse transcriptase inhibitors. J Mol Graph Model;28:146-155.
41. Hu R., Barbault F., Delamar M., Zhang R. (2009) Receptor- and ligand-based 3D-QSAR study for a series of non-nucleoside HIV-1 reverse transcriptase inhibitors. Bioorg Med Chem;17:2400-2409.
42. Cichero E., Cesarini S., Fossa P., Spallarossa A., Mosti L. (2009) Thiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses. Eur J Med Chem;44:2059-2070.
43. Chiu T.-L., So S.-S. (2004) Development of neural network QSPR models for hansch substituent constants. 2. applications in QSAR studies of HIV-1 reverse transcriptase and dihydrofolate reductase inhibitors. J Chem Inf Comput Sci;44:154-160.
44. Cramer R.D. III, Patterson D.E., Bunce J.D. (1988) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc;110:5959-5967.
45. Garg R., Kurup A., Gupta S.P. (1997) Quantitative structure-activity relationship studies on some acyclouridine derivatives acting as anti-HIV-1 drugs. Quant Struct-Act Rel;16:20-24.
46. Luco J.M., Ferretti F.H. (1997) QSAR based on multiple linear regression and PLS methods for the anti-HIV activity of a large group of hept derivatives. J Chem Inf Comput Sci;37:392-401.
47. Goodsell D.S., Morris G.M., Olson A.J. (1996) Automated docking of flexible ligands: applications of autodock. J Mol Recognit;9:1-5.
48. Morris G.M., Huey R., Olson A.J. (2008) Using AutoDock for ligand-receptor docking In: Current Protocol in Bioinformatics. Malden, MA: John Wiley & Sons, Inc.; 14 p, chapter 8; unit 8.
49. Trott O., Olson A.J. (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem;31:455-461.
50. Insight-II, version (2005) molecular modelling package, and DelPhi version 30 solvation program, 2000. San Diego, CA: Accelrys, Inc.
51. Wold S., Rhue A., Wold H., Dunn W.J. III (1984) The collinearity problem in linear regression. the partial least squares (PLS) approach to generalized inverses. SIAM J Sci Stat Comput;5:735-743.
52. Wold S. (1991) Validation of QSAR's. Quant Struct-Act Rel;10:191-193.
53. Clark M., Cramer R.D. III (1993) The probability of chance correlation using partial least squares (PLS). Quant Struct-Act Rel;12:137-145.
54. Tanaka H., Takashima H., Ubasawa M., Sekiya K., Nitta I., Baba M., Shigeta S., Walker R.T., De Clercq E., Miyasaka T. (1992) Synthesis and antiviral activity of deoxy analogs of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) as potent and selective anti-HIV-1 agents. J Med Chem;35:4713-4719.